A novel homozygous c.301T > C, p.Y101H variant in the GNA11 gene is implicated in familial hypocalciuric hypercalcemia type 2 in a proband with the heterozygous variant present in mother and father – A case report

Familial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous autosomal dominant disorder of calcium homeostasis, which is usually asymptomatic and characterized by low or normal phosphorus, inappropriately normal or elevated PTH, and low fractional excretion of calcium (FECa) in addition to hypercalcemia. Loss-of-function mutations in the G protein subunit alpha 11 (GNA11) gene, an important downstream signaling partner of the Calcium-sensing receptor (CaSR), cause FHH type 2. We reviewed the GNA11 gene-associated FHH type 2. A 14-year-old male was referred due to hypercalcemia (2.89 mmol/L). Slightly elevated PTH (7.95 pmol/L), but normal phosphorus (1.19 mmol/L), alkaline phosphatase (271 U/L), magnesium (0.95 mmol/L), and albumin (43 g/L) levels were detected. The FECa was found to be low when serum calcium was high (FECa was <0.01%, and <0.01% on two separate tests). A homozygous c.301T > C, p.Y101H variant was detected in the GNA11 gene. The same variant was detected heterozygous for both parents. While the calcium levels of the mother and father were normal, their spot urinary FECa was found low (Ca: 2.47 mmol/L, FECa: <0.01%, and Ca: 2.45 mmol/L, FECa: 0.01%, respectively). Hypocalciuria without hypercalcemia can be detected in cases heterozygous for the GNA11 gene mutation. Severe hypercalcemia may not occur in homozygous cases.